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Genetic vaccine technology has been considerably devel-
oped within the last two decades. This cost effective and 
promising strategy can be applied for therapy of cancers 
and for curing allergy, chronic and infectious diseases, 
such as a seasonal and pandemic influenza. Despite nu-
merous advantages, several limitations of this technolo-
gy reduce its performance and can retard its commercial 
exploitation in humans and its veterinary applications. 
Inefficient delivery of the DNA vaccine into cells of im-
munized individuals results in low intracellular supply 
of suitable expression cassettes encoding an antigen, in 
its low expression level and, in turn, in reduced immune 
responses against the antigen. Improvement of DNA de-
livery into the host cells might significantly increase ef-
fectiveness of the DNA vaccine. A vast array of innova-
tive methods and various experimental strategies have 
been applied in order to enhance the effectiveness of 
DNA vaccines. They include various strategies improving 
DNA delivery as well as expression and immunogenic 
potential of the proteins encoded by the DNA vaccines. 
Researchers focusing on DNA vaccines against influenza 
have applied many of these strategies. Recent examples 
of the most successful modern approaches are discussed 
in this review.
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INTRODUCTION
The concept of DNA vaccines has been experimen-
tally proven about two decades ago (Fynan et al., 1993; 
Mor, 1998). Since that time they were shown to induce 
potent T- and B-cell immune responses against a vari-
ety of antigens (Khan, 2013). This intriguing strategy 
of vaccination is based on the following principles: (i) 
a gene encoding an antigen can be expressed in trans-
fected cells and (ii) a foreign antigenic protein produced 
within the host cells can induce humoral and cellular im-
mune responses. When a DNA vaccine (consisting of 
an animal expression plasmid and a carrier) is injected 
into the tissue, the plasmid molecules have to overcome 
a great obstacle of cell membrane and next, they must 
be transported into the nucleus. Both, the somatic cells 
(e.g. myocytes, keratinocytes) and the nearby antigen pre-
senting cells (APCs) can be transfected at the immuni-
zation site. Production of the vaccine protein relies on 
transcription and translation of the administered vaccine 
DNA within the transfected cells (Fig. 1). Thus, the for-
eign antigenic proteins are endogenously produced, intra-
cellularly processed and their fragments (antigenic pep-
tides) are exposed on the cell surface by the MHC class 
I and class II molecules involved in induction of cellular 
and humoral immunity. Three mechanism of immuno-
genicity of DNA vaccines are possible: (i) presentation 
of antigens by myocytes or keratinocytes to CD8+ cells 
directly through their MHC class I pathway, (ii) direct 
transfection of APCs and (iii) phagocytosis of transfect-
ed somatic cells by APCs which present the antigen to T 
cells. For the details of the mechanism of DNA vaccines 
action the reader is referred to several excellent reviews 
(Iurescia et al., 2014; Khan, 2013; Kutzler & Weiner, 
2008; Li et al., 2012b; Liu, 2011; Moss, 2009).
DNA vaccines, as all innovatory preparations, have 
not only advantages but also disadvantages. Most of 
pros and cons are listed in Fig. 2, however for the more 
extensive discussion the reader is referred to the reviews 
mentioned above. Shortly, this strategy is superior to 
others mainly due to its simplicity and low cost of pro-
duction, omitting the steps of propagation and isolation 
*e-mail: asirko@ibb.waw.pl
Abbreviations: HA, hemagglutinin; M1, matrix protein; M2, ion-
channel protein; NP, nucleoprotein; NA, neuraminidase; LPAIV, low 
pathogenic avian influenza virus; HPAIV, highly pathogenic avian 
influenza virus; LAIV, live attenuated influenza vaccine; MIV, mono-
valent inactivated vaccine; HI, hemagglutination inhibition; SPF, 
specific pathogen-free; PEG, polyethylene glycol; NP, nanoparticles; 
VLP, virus-like particle; LEC, linear expressing cassette.
Figure 1. The overall mechanism of DNA vaccine action.
Plasmid DNA can be transfected into antigen presenting cells 
(APCs) or somatic cells. Thus created protein antigen can be se-
creted from the cell and activate B cells, leading to antibody pro-
duction, or activate APCs. APCs are activated by direct transfection 
or cross presentation of antigens, and migrate to the draining 
lymph nodes, where antigenic peptides are presented by major 
histocompatibility complexes (MHC I and MHC II), and stimulates 
T cells. Modified according to (Iurescia et al., 2014; Xu et al., 2014).
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of antigens. In case of viral diseases, when the patho-
gen’s proteins are produced by host cells, DNA vaccina-
tion leads to immunization with an antigen completely 
the same as during natural infection. It is also worth to 
clarify that the often mentioned threats (disadvantages) 
of DNA vaccines, such as a possibility of antibody pro-
duction against DNA or insertion of foreign DNA into 
the host genome (genetic transformation), appeared to 
be unconfirmed or, if detected, remains at an insignifi-
cant level (Klinman et al., 2010). Further objections are 
related to the fact that the efficiency of such vaccines is 
not as encouraging in humans and large animals as it is 
in small animal models.
DNA VACCINES AGAINST INFLUENZA
Influenza is one of the most important illnesses in 
modern world, causing great public health loses each 
year, due to lack of medicines and broadly protective, 
long lasting vaccines. Moreover, due to its zoonotic 
potential and high changeability, it brings a continu-
ous threat of a new global pandemic. Therefore many 
researches are focused on preparing new solutions for 
fighting and controlling influenza. DNA vaccines against 
influenza virus can be divided into two main categories, 
(i) vaccines for veterinary purposes, mainly against H5N1 
for poultry, but also against other influenza strains for 
pigs or horses and (ii) vaccines for human seasonal and 
pandemic influenza, including H5N1 prospective pan-
demic, tested mainly in mice and ferrets, although some 
clinical trials are already published (Ledgerwood et al., 
2011; Smith et al., 2010; Girard et al., 2013). Despite dif-
ferences in the regulatory requirements for human and 
animal vaccines, the main course of technology is the 
same (van Drunen Littel-van den Hurk et al., 2004; Hori-
moto & Kawaoka, 2006). Currently, inactivated vaccines, 
prepared from egg-propagated viruses are commonly 
used for human and animal immunizations against in-
fluenza (Kreijtz et al., 2009; Spackman & Swayne, 2013; 
Capua & Cattoli, 2013). Nevertheless, it is clear that 
contemporary influenza vaccines should be more flex-
ible, universal and, in particular, they need to be pro-
duced faster, in case of a new influenza outbreak. Such 
requirements stimulate development of various “new 
generation” vaccines against influenza virus. Subunit 
vaccines and DNA vaccines against influenza virus are 
often based on hemagglutinin (HA), the main viral an-
tigen. Other viral proteins are used rather rarely, usually 
together with HA, however the sequences encoding NA, 
M2, NP and M1 were also used in some DNA vaccines 
(Lim et al., 2013; Patel et al., 2012b). These proteins are 
usually less immunogenic than HA and are insufficient 
to obtain the protective response, particularly in case of 
highly pathogenic avian influenza viruses (HPAIV), how-
ever some exceptions were reported (Shen et al., 2012). 
Frequently, these less immunogenic, yet also less vari-
able, antigens are used to complement the responses and 
make them less specific to recognize a broader spectrum 
of viruses, thus more suitable for a universal influenza 
vaccine (Osterhaus et al., 2011). A broad range of im-
munity can be also achieved by designing the polyvalent 
DNA vaccines composed of several sequences of HA 
antigens originating from distinct strains. For example, 
the cross-immunity and cross-protection were obtained 
in mice immunized with a DNA vaccine based on the 
HA sequences from two distinct strains of H5N1 (Gao 
et al., 2012), or with a trivalent vaccine containing three 
HA sequences selected from a panel of 17 sequences 
representing all H5N1 clades (Zhou et al., 2012). In most 
of the reported cases vectors with a CMV promoter 
were used to drive the transcription of a gene encoding 
an antigen, however in many chicken studies the chicken 
β-actin promoter has been used as well (Williams, 2013).
In this review we focus on recent and most innova-
tive research trends significantly advancing work on the 
DNA vaccine against influenza virus. The approaches 
discussed here are schematically shown in Fig. 3. They 
include: (i) sequence optimizations in order to improve 
the level of expression and to direct antigen into appro-
priate cellular compartments, (ii) complexing of DNA 
with carriers to improve its uptake and stability, (iii) ad-
dition of chemical and biological adjuvants of the im-
mune response and (iv) employment of mechanical de-
vices for efficient and precise application and (v) mixed 
vaccination (Ferraro et al., 2011; Ulmer, 2002; van den 
Figure 2. Advantages and disadvantages of DNA vaccines.
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Berg et al., 2010). Some examples of studies described in 
this report are listed in Table 1 and Table 2.
SEQUENCE MODIFICATIONS
Codon optimization
Codon optimization strategy is used broadly in the 
development of DNA vaccines against influenza virus. 
This approach is facilitated by recent advances in bioin-
formatics methods, resulting in availability of new pro-
grams enabling effective sequence adaptation. Codon 
optimization has been mentioned in many reports, how-
ever details of sequence modifications are often omitted 
and no wild type sequence is used in immunizations for 
comparison. For example, rabbits immunization with 
DNA vaccines based on different HA (from H5N1) 
using sequence optimized to the mammalian system re-
sulted in a potent production of anti-HA antibodies with 
broad cross reactivity (Wang et al., 2011). Similarly, posi-
tive effects (detectable humoral and cellular responses 
and protection against challenge with a homologous vi-
rus) were observed in mice immunized against H5N1 
HPAIV and in ferrets immunized against seasonal H1N1 
using a codon-optimized HA-based DNA vaccine (Pa-
tel et al., 2012a). A successful immunization of Japanese 
quails with the DNA vaccine based on HA from H5N1 
HPAIV and containing sequence optimized for chicken 
codon usage was reported (Li et al., 2012a). The birds 
obtained three intramuscular doses of the plasmid (10, 
15, 30 or 60 µg) and the challenge experiment with a 
homologues virus was conducted two weeks later. An-
tibody responses measured by hemagglutinin inhibition 
(HI) test showed 100% of seroconversion in the groups 
immunized with 30 and 60 µg and 60–70% of serocon-
version in the groups immunized with 10 and 15 µg of 
DNA. The mortality (20%) after the challenge was ob-
served only in the lowest dose group. An apparent very 
good efficacy of this DNA vaccine formulation is clear-
ly emphasized by the fact that all surviving birds were 
completely protected and no virus shedding or clinical 
signs of the infection were observed.
In the case when the efficiency of the HA codon-
optimized, DNA vaccine against low pathogenic (LP) 
H6N2 virus was compared to the DNA vaccine based 
on the wild type HA, no significant differences were 
observed in responses of chickens to the optimized and 
not optimized variant of the DNA vaccine, regardless 
of the dose (Shan et al., 2011). The optimized sequence 
was shifted to the codon usage bias optimal for chicken 
(resulting in 74.8% similarity to the wild type nucleotide 
sequence).
Also in our studies, effectiveness of a DNA vaccine 
based on H5 HA and containing codons optimized to 
the chicken host has been demonstrated (Stachyra et al., 
2014). Nevertheless, our subsequent chicken immuni-
zation studies with the wild type sequence and the se-
quence with optimized codons failed to prove that the 
optimized sequence is superior over the wild type se-
quence in mounting the immune responses (data not 
published).
Figure 3. General strategies used to improve efficacy of DNA vaccines against influenza described in this report.
Table 1. Selected DNA vaccination studies against influenza performed in a mouse model.
Subtype of the template virus Strategy for improvement Reference
H5N1 Codon optimization, rare peptides as an adjuvant Patel et al., 2012a
H5N1 CD40 gene as an adjuvant Chen et al., 2013
H3N2 Chitosan nanoparticles as a carrier Zhao et al., 2011
H3N8 Codon optimization, needle-free application Ault et al., 2012
H5N1 Electroporation application Xu et al., 2011
H1N1, H3N2 Head-less HA, electroporation application, VLPs boost Steel et al., 2010
H1N1, H1N1 Linear cassette, electroporation application Shen et al., 2012
H5N1 Consensus HA, point mutations, electroporation application Chen et al., 2011
H5N1 Cleavage site deletion, micro needle application Kim et al., 2012
H5N1 Point mutations, VLPs boost Lin et al., 2012
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In summary, the advantages of codon optimization 
approaches are still somewhat controversial.
Other modifications
Other frequently reported sequence modifications 
(mainly within the HA gene) used in DNA vaccines 
against influenza include: (i) deletions of the signal pep-
tide or the transmembrane region (Wang et al., 2011), (ii) 
removing of the proteolytic cleavage site, which is re-
lated to the virulence (Kim et al., 2012; Stachyra et al., 
2014), (iii) point mutations changing single amino acids 
to achieve a better cross reactivity (Chen et al., 2011), 
(iv) point mutations changing glycosylation sites (Lin et 
al., 2012), (v) using antigen fragments, such as single do-
mains or the stem region (Steel et al., 2010) and (vi) cre-
ating a synthetic gene based on the consensus sequence 
obtained by comparison of sequences available in data-
bases (Chen et al., 2011). Unfortunately, none of these 
approaches achieved a significant breakthrough concern-
ing the efficacy of a DNA vaccine.
ADJUVANTS
Peptides
Some novel formulations of the adjuvants suitable 
for DNA vaccines were recently proposed (Patel et al., 
2012a). For example, short polypeptides (rare or non-
existing in vaccinated organisms) were designed after in 
silico screening of the UniProt database. They were used 
as adjuvants of the DNA vaccine for mice based on H5 
HA. Combination of the DNA vaccine with one of the 
discovered pentamers (KWCEC) was significantly more 
effective than the HA plasmid alone. A subsequent chal-
lenge experiment indicated complete (100%) protection. 
Similar results were also observed in ferrets, using the 
same pentamer and the plasmid with H1 HA sequence. 
The authors claim that rare amino acid sequences could 
act as immune modulators positively contributing to the 
antigen-specific immune activation, however, the mecha-
nism is not further explained.
Cytokines
Various cytokines or their expression cassettes have 
been applied as biological adjuvants of anti-influenza 
DNA vaccines (van Drunen Littel-van den Hurk et al., 
2004). For example, combinations of the DNA sequence 
encoding HA from H5N1 HPAIV with the cDNAs en-
coding either chIL-15 or chIL-18, known to induce the 
inflammatory response, were administered intramuscu-
larly (in two doses) to chickens (Lim et al., 2012). The 
group inoculated with a mixture of the plasmids encod-
ing HA and chIL-15 gave the best results in the hemag-
glutinin inhibition (HI) test. Later, the same team immu-
nized chickens with combinations of plasmids encoding 
chIL-15 or chIL-18 with plasmids encoding N1 NA or 
NP (Lim et al., 2013). Both plasmids encoding interleu-
kins improved responses against N1 NA and NP, how-
ever, the highest immunological potential had the combi-
nation of the plasmids encoding N1 NA and IL-15. Ad-
ditional in vitro results indicated that the plasmids were 
stable in the muscles of immunized chickens for as long 
as 6 week after vaccination. Surprisingly, expression of 
the vaccine antigens was also detected by real time PCR 
in spleens.
Other biological adjuvants
Proteins involved directly or indirectly in the immuno-
logical response, in stress and danger signaling, are good 
candidates for adjuvants of immunological reactions. 
DNA fragments encoding four such novel proteins were 
applied in DNA vaccines against influenza.
The first example is CD40, a member of the tumor 
necrosis factor receptor family, expressed in many cells 
and playing an important role in regulation of humoral 
and cell-mediated immune responses. Mice immunization 
with the plasmids encoding HA from H5N1 HPAIV in 
combination with the plasmid encoding CD40 was re-
cently reported (Chen et al., 2013). Vaccine formulations 
containing the CD40 encoding plasmid induced much 
higher humoral responses than vaccine formulations 
with HA encoding plasmid alone. Additionally, an ob-
served increase in expression of genes for Th2 cytokines, 
namely IL-2 and IL-6, confirms that CD40 indeed posi-
tively affected the humoral response.
Efforts of another group have been concentrated on 
chicken MAD5, a pattern recognition receptor (PRR) 
which senses danger signals associated with a virus in-
fection and contributes to the activation of signaling 
and to the secretion of type I IFN (Liniger et al., 2012). 
The sequence encoding N-terminal part of chMAD5 
was cloned into an expression vector as a bicistronic ex-
pression plasmid with the sequence encoding HA from 
H5N1 HPAIV and used to immunize SPF chickens with 
two suboptimal doses. Vectors expressing either HA or 
chMAD5 alone were applied as a control. Co-expression 
of chMAD5 with HA led to considerable amplification 
of the anti-HA humoral response, high protection level 
(5 per 6 chickens survived the challenge with a homolo-
Table 2. Selected DNA vaccination studies against influenza performed in a chicken model.
Subtype of the template virus Strategy for improvement Reference
H6N2 Codon optimization, electroporation application Shan et al., 2011
H5N1 Codon optimization, cleavage site deletion, Lipofectin as a carrier Stachyra et al., 2014
H5N1 IL-15 and IL18 genes as an adjuvant Lim et al., 2012
H5N1 IL-15 and IL18 genes as an adjuvant Lim et al., 2012
H5N1 MAD5 gene as an adjuvant Liniger et al., 2012
H5N1 MDPI gene as an adjuvant Jalilian et al., 2010
H5N1 ESAT-6 gene as an adjuvant Oveissi et al., 2010
H5N1 Silver nanoparticles as a carrier Jazayeri et al., 2012
H5N1 Electroporation application Ogunremi et al., 2013
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gous virus) and reduced virus shedding in tracheal and 
cloacal swabs.
Mycobacterial DNA-binding protein I (MDPI) acting 
as an immunodominant antigen stimulating responses via 
TLR9 pathway was tested in a vaccine against H5N1 for 
chickens (Jalilian et al., 2010). Triple intramuscular vac-
cination of chickens with plasmids encoding MDPI and 
HA (in a combination or each alone) indicated higher 
humoral responses in the group immunized with com-
bination of the plasmids. Although the observed differ-
ences in humoral response (ELISA and HI) were statis-
tically insignificant, the authors proposed that usage of 
the MDPI-encoding gene as a genetic adjuvant could be 
beneficial.
In a similar study, combination of the plasmid con-
taining mycobacterial ESAT-6 gene encoding a protein 
involved in bacterial virulence and the plasmid encod-
ing H5 HA was tested in chickens (Oveissi et al., 2010). 
All chickens were seropositive in the group that received 
the plasmid combination, while only 3 out of 8 chick-
ens were positive in the group vaccinated solely with the 
plasmid encoding HA. Statistically significant differences 
were also found in the HI titers.
CARRIER FORMULATIONS
One of the strategies reported, was an intramuscu-
lar immunization of mice with a DNA vaccine encod-
ing HA from H3N2 swine influenza virus encapsulated 
in chitosan nanoparticles (Zhao et al., 2011). The naked 
HA-encoding plasmid was injected as a control. Serum 
IgG titer (tested by ELISA) was significantly higher 
in the group vaccinated with nanoparticles than in the 
group vaccinated with the naked plasmid. Furthermore, 
the lymphocyte proliferation test indicated that nanopar-
ticles also enhanced cellular immunity. The nanoparticles 
showed no cytotoxicity during in vitro tests. In our stud-
ies, DNA vaccine based on HA from H5N1 HPAIV 
with the commercially available liposomal carrier (Lipo-
fectin, Life Technologies, USA) was successfully used 
for immunization of chickens (Stachyra et al., 2014). 
Antibody response measured by ELISA and the HI test 
indicated an obvious advantage of vaccination with the 
carrier. Moreover, two doses of such adjuvanted vac-
cine were sufficient to protect SPF chickens against the 
challenge with homologous and heterologous (distinct 
clade) HPAIVs, however, non adjuvanted vaccine was 
not tested in the challenge experiments. Silver nanopar-
ticles were used as carriers in a DNA vaccine based on 
H5 HA, applied orally to chickens (Jazayeri et al., 2012). 
They were composed of Ag covered with PEG and 
complexed with a DNA plasmid expressing HA. Not 
only immunological responses but also presence of the 
nanoparticles in chicken intestinal mucosa was tested for 
a limited time of 48 hours. Interestingly, the H5 mRNA 
was detected in tissue samples as early as 1h post im-
munization. Cellular response was significantly higher 
(and it was increasing till day 28) in the group vaccinated 
with HA nanoparticles. Also, the HI titer in this group 
was high and maintained for a long time. These results 
indicate huge advantages of nanoparticle approaches in 
oral applications that might be the most desirable vac-
cine formulations for mass usage in the poultry industry.
Very good results of clinical trials with anti-influenza 
DNA vaccines containing Vaxfectin® (Vical, San Diego, 
CA, USA), a liposomal carrier, were reported (Smith et 
al., 2010). According to the information provided on the 
company webpage (http://www.vical.com/technology/
vaxfectin/default.aspx) Vical is currently developing sev-
eral products that utilize Vaxfectin® as an adjuvant, how-
ever it is unclear if a DNA vaccine against influenza is 
one of these potential products.
MECHANICAL DEVICES
Jet injection
Effectiveness of conventional intramuscular injec-
tion and a needle-free injection system (PharmaJet, Inc., 
Golden, CO, USA) was compared in pigs immunized 
with DNA plasmids carrying the HA sequences from 
H1N1 (seasonal and pandemic) and H3N2, using mono-
valent or trivalent formulations (Gorres et al., 2011). The 
HI titers and virus neutralization were robust and simi-
lar in all experimental groups regardless of the route of 
administration. Groups vaccinated with monovalent vac-
cines and challenged with pandemic H1N1 strain showed 
full reduction of virus shedding and lack of histopatho-
logical changes in lungs. The authors claimed that the 
needle-free delivery worked with the same efficacy as 
the conventional injection. It can be thus an interesting 
alternative for veterinary and human DNA vaccine ap-
plications. Recently, immunization of ponies with mono-
valent or trivalent DNA vaccines encoding HAs from 
different H3N8 equine influenza viruses was reported 
(Ault et al., 2012)2012. Preliminary studies were first con-
ducted in a mouse model and the vaccine efficacy was 
confirmed by the HI test. Next, ponies received three 
doses of the vaccine by intramuscular or subdermal ap-
plications using the needle-free system (PharmaJet, Inc., 
Golden, CO, USA). Challenge with a heterologous virus 
was performed 7 weeks after the third dose and was 
followed by serological assays, clinical monitoring, virus 
shedding test and cytokine expression profiling. A cer-
tain level of cross-response was obtained in the group 
immunized by the needle-free device that received the 
trivalent formulation by subdermal application. Interest-
ingly, antibody titers were slightly higher in the mono-
valent vaccine group immunized with the needle-free 
system than with the syringe, which suggested that this 
way of vaccine administration may enhance immune re-
sponses. However, no significant differences between the 
conventional and needle-free application was observed in 
case of the degree of protection, virus shedding and clin-
ical symptoms. All of them were significantly reduced in 
all immunized groups compared to the non-immunized 
controls. Thus, the needle-free system is at least compa-
rable to the conventional needle vaccination, yet it could 
be a more convenient alternative for massive vaccina-
tions of larger species.
Jet injection was also one of the routs tested in clini-
cal trials of anti-influenza DNA vaccines (Smith et al., 
2010). Plasmids encoding consensus NP and M2 from 
seasonal strains (H3N2 and H1N1) and HA from H5N1 
HPAIV were complexed with Vaxfectin in mono- or tri-
valent formulations and injected intramuscularly either 
by the conventional syringe with a needle or by the nee-
dle-free device (Biojector 2000, Bioject Medical Technol-
ogies, Inc., Portland, OR, USA), at doses ranging from 
0.1 to 1 mg. Immunization was repeated 3 weeks later 
and after 2 additional weeks the humoral serum response 
was measured as well as the potential adverse effects 
were monitored. All doses, regardless of the immuniza-
tion method, were well tolerated without serious adverse 
effects or discontinuations. The monovalent formulation, 
containing only the HA gene, was effective (HI titers 
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>40) at higher doses (0.5 and 1 mg) in both, needle and 
needle-free applications. The trivalent formulations con-
taining three influenza genes were less effective, prob-
ably due to proportionally smaller dose of HA sequences 
in their composition.
Electroporation
Electroporation is broadly used under laboratory con-
ditions for improving DNA uptake by the cells. It can 
also improve the immune response by generation of the 
stress signals in tissues of the vaccinated individual. The 
weak point of this method is that the electroporation pa-
rameters have to be carefully optimized in order to mini-
mize tissue damage while maintaining the high efficacy 
of DNA uptake (van Drunen Littel-van den Hurk et al., 
2004).
Electroporation was successfully used in an experi-
ment with mice immunized with DNA vaccines based 
on HA and NP from H5N1 where even the cross-reac-
tive response against heterologous H9N2 was achieved 
(Xu et al., 2011).
Other experiments have been performed using a DNA 
plasmid with partial HA (“stem” region) from human 
H1N1 and H3N2 (Steel et al., 2010). Mice were immu-
nized with the DNA vaccine (injection was followed by 
electroporation), boosted with virus like particles (VLPs) 
and challenged. Sera from groups immunized with plas-
mid encoding H1 stem cross-reacted in ELISA with the 
broad panel of hemagglutinins (H1, H2, H3 and H5). 
Furthermore, despite the lack of neutralizing antibodies, 
immunized mice were protected from infection during 
challenge and had only 6% body weight loss.
Slightly different strategy was used by another group 
working with a synthetic linear expressing cassette (LEC) 
encoding the M1 and NP genes from the seasonal H1N1 
virus (Shen et al., 2012). Mice received three intradermal 
doses of the vaccine followed by electroporation. Plas-
mid vectors containing all genes were also administrated 
as a control. ELISA test and flow cytometry analysis 
indicated that electroporation significantly enhanced the 
response to immunization with LECs. The challenge ex-
periment using homologous (H1N1) and heterologous 
(H5N1) viruses was performed 10 weeks later, however 
vaccine effects were not clearly indicated in this study. 
Nevertheless, a DNA vaccine based on other viral genes 
than HA can ensure some protection.
Another electroporation study focused on two con-
sensus HA sequences of H5N1 viruses from clade 1 and 
2 (Chen et al., 2011). Mice immunization was followed 
by a challenge. Protection against viruses even from dif-
ferent clades was high (90–100%). These results indicate 
suitability of the “consensus” approach in development 
of a universal vaccine against influenza.
Immunization of chickens with a DNA vaccine en-
coding HA from H6N2 LPAIV was more effective 
when electroporation was following the intramuscular 
injections, where the corresponding group immunized 
by injection without electroporation had an almost 
3-fold lower average HI titer (Shan et al., 2011). In-
teresting results were reported by other researchers, 
who showed protective immune response in chickens 
after a single dose immunization with electroporation 
(Ogunremi et al., 2013). Animals were immunized with 
a plasmid containing a sequence encoding HA from 
H5N1 using 10, 100 or 250 µg of the plasmid. An 
intramuscular injection was immediately followed by 
electric pulses from a TriGrid electrode (Ichor Medi-
cal Systems, San Diego, CA, USA). Results of the HI 
test and competitive ELISA showed 100% of serocon-
version in groups immunized by electroporation with 
100 and 250 µg of DNA. On the contrary, groups 
immunized with the same vaccine doses but without 
electroporation had low HI titers and none of them 
was seropositive. The challenge experiments with het-
erologous H5N2 HPAIV, performed one week after 
immunization indicated that all chickens immunized 
with higher doses (100 or 250 µg) with electropora-
tion survived infection. Chickens from these groups 
showed no clinical symptoms, whereas birds receiving 
vaccine without electroporation showed a similar pat-
tern of susceptibility as those injected with the control 
plasmid. It is also worth to mention that all seroposi-
tive birds, even those that were immunized with 10 
µg dose of the vaccine, turned out to be protected 
against the challenge. This study showed a really 
promising perspective for reducing the number of the 
doses of the protective DNA vaccine by application 
of electroporation.
Other devices
Immunization of rabbits with plasmids containing two 
variants of an optimized HA gene, based on HP H5N1, 
via Helios gene gun (BIO-Rad, USA) has been reported 
(Wang et al., 2011). Animals received three doses of plas-
mid DNA into a shaved abdominal skin. Humoral re-
sponses were detected by serological assays (ELISA, HI 
and micro neutralization). Considering a relatively small 
dose of plasmid DNA (36 µg) used per rabbit (average 
weight of a rabbit is about 2 kg) these results strong-
ly validate effectiveness of immunization with the gene 
gun. However, this method has many limitations. For 
example, only relatively small amounts of DNA can be 
coated by gold beads.
Usage of microneedles for intradermal vaccination 
is a novel and recent approach (Kim et al., 2012). The 
DNA vaccine used in this work was based on HA from 
H5N1 HPAIV. Plasmid DNA (about 3 µg per dose) was 
used to coat 700 µm-long microneedles (5 needles per 
array). Mice were immunized (3 times, 5 weeks apart) 
into depilated skin on the back and an intramuscular 
injection was performed as a control. The antibody titers 
(ELISA, HI) were already significantly higher after the 
second boosting in groups immunized with micronee-
dles. Additionally, a clear difference in the isotyping pro-
file with IgG2a dominant in microneedle application was 
observed. A challenge with a homologous virus was per-
formed 21 weeks post immunization. A quite high pro-
tection level in the group vaccinated with micronedles 
(67% of survival) was observed, while the group injected 
conventionally had no resistance — all mice from this 
group died on the 8th day post challenge.
OTHER STRATEGIES
Combination of a DNA vaccine with other vaccine 
formulations is often beneficial. DNA vaccines are most-
ly used as a “primer” followed by a boost with other 
kinds of vaccines. A good example of such approach is 
the recently reported immunization of mice with a DNA 
vaccine encoding H5 HA, followed by application of 
VLPs consisting of HA, NA, M1 and M2 produced in a 
baculovirus system (Lin et al., 2012). Analysis of the HI 
titers indicated significantly better results for DNA–VLP 
schedule in comparison to DNA–DNA or VLP–VLP 
vaccinations.
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VLPs were also used as a boost immunization in 
the previously mentioned report (Steel et al., 2010). 
Briefly, the results were good, but no control DNA 
immunizations was done in this experiment. Another 
group boosted their DNA vaccine with live attenuated 
and inactivated virus particles (LAIV) in ferrets stud-
ies (Suguitan et al., 2011). Primarily, a set of recom-
binant H5N1 influenza viruses from different clades 
were prepared as LAIV formulations for the “boost-
er” dose, while an optimized (no details provided) HA 
sequence was cloned into the respective expression 
vector. Animals were immunized in various combina-
tions of the prime-boost formulations and then they 
were subsequently challenged. Humoral responses 
(ELISA) were very poor in the case of DNA–DNA 
immunization, while the DNA–LAIV schedule in-
duced even a slightly higher response than LAIV–
LAIV or LAIV–DNA immunization. Microneutraliza-
tion assay with homologous and heterologous viruses 
confirmed a high potential of this mixed prime-boost 
regiment. Moreover, after challenge the effective re-
duction of viral titers in lungs was observed only in 
the DNA–LAIV and LAIV–LAIV groups. Therefore, 
DNA priming–LAIV boosting could be a good alter-
native for two doses of attenuated vaccines, which 
are very efficient but rather inconvenient due to ne-
cessity of live pathogen handling. In another report, 
mixed immunizations of mice and ferrets using plas-
mid DNA and adenoviral vector system was described 
(Rao et al., 2010). Initially, immunogenicity of the 
conventional plasmid vectors encoding HA, M2 and 
NP from HP H5N1 was checked in mice and the 
best combination was chosen. Next, sequences of the 
target genes were cloned into three separate, replica-
tion defective, recombinant adenovirus vectors and 
the viruses were produced by serial passages in com-
plementing cells. Then, male ferrets were immunized 
with mixed DNA plasmid vectors at a total dose of 
250 µg intramuscularly (3-fold; 3 weeks apart). Three 
weeks after the last dose of DNA vaccine, the animals 
were injected with 1010 particles of recombinant ad-
enoviruses, and 10 weeks later they were challenged 
with a homologous virus. A good level of protection 
and significantly high antibody levels were observed 
in the groups immunized with plasmids encoding HA 
alone or with addition of plasmids encoding M2 and 
NP. Those additional antigens were not able to induce 
resistance in the absence of HA.
Prime-boost strategy with plasmid DNA and mon-
ovalent inactivated vaccine (MIV) was used also in 
phase 1 clinical trials against HP H5N1 (Ledgerwood 
et al., 2011). Several schedules were compared, includ-
ing intramuscular single or double dose with 4 mg of 
HA DNA followed by immunization with 90 µg of 
MIV in 4 or 24 week intervals. MIV-MIV immuniza-
tion was conducted as a control. ELISA, HI and mi-
cro neutralization tests indicated a very good level of 
responses in the case when the time between DNA 
and MIV doses was long (24 weeks apart). It is also 
worth mentioning that two doses of DNA with a 
shorter (4 week) interval resulted in a better response 
than MIV-MIV vaccination with the same (4 week) 
schedule.
FUTURE PERSPECTIVES
A continuous progress in the development and ap-
plication of DNA vaccines is observed. Three DNA 
vaccines have already been licensed for veterinary pur-
poses (for horses — against West Nile virus, for fishes 
— against infectious hematopoietic necrosis virus, and 
for dogs — against canine malignant melanoma). No 
DNA vaccine for humans is licensed, but many candi-
dates are under clinical evaluations (see: http://clinical-
trials.gov/). Regulatory requirements for DNA vaccines 
are published in several guidance documents containing 
recommendations for production and safety evaluation 
of DNA vaccines intended for use in humans (EMEA, 
2001; FDA, 2007; WHO, 2007). There are solid basis 
for expectations that a DNA or a partial-DNA vaccine 
product will be approved for human use against pan-
demic and highly pathogenic H5N1 virus (in case of a 
future pandemic) in a few years (Ferraro et al., 2011). 
Additionally, the DNA vaccine for veterinary purposes 
against avian influenza, and possibly against equine or 
swine influenza, will be developed. They might be quite 
important especially for Asian countries, where infec-
tions of poultry (and humans) frequently occur. In Euro-
pean countries, due to the current law restrictions, DNA 
vaccine will be probably initially approved for some spe-
cial cases, like immunizations of valuable flocks or zoo 
collections, but not for mass applications (Spackman & 
Swayne, 2013). Hopefully, work on improvement of the 
efficacy of DNA vaccines will not stay behind research 
on other new generation vaccines, and more and more 
effective and safe strategies will be invented.
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